-0.36 (-1.788%)Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Value
Consensus
Price
Weak
Earnings
Neutral
Earnings
Neutral
Dividends
Very Weak
Capital Efficiency
Neutral
Balance Sheet
Very Strong
Website
Syndax Pharmaceuticals Inc
Telephone
1.781.419.1400
Address
floor 9, 730 Third Avenue, New York, NY 10017
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 8.59 - 25.59
Trade Value (12mth)
US$8,212,697.00
1 week
-0.49%
1 month
-8.83%
YTD
-5.49%
1 year
86.22%
All time high
29.86
EPS 3 yr Growth
34.10%
EBITDA Margin
-158.40%
Operating Cashflow
-$323m
Free Cash Flow Return
-62.70%
ROIC
-55.40%
Interest Coverage
-8.10
Quick Ratio
4.10
Shares Outstanding (Fully Diluted)
88m
HALO Sector
Healthcare
Next Company Report Date
02-Mar-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 01 May 26 | |
| 01 May 26 | |
| 01 May 26 | |
| 01 May 26 | |
| 27 February 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -2.98 | -3.72 | -3.29 | | | | ||
EPS (Fully Diluted) | $ | | | | | -2.98 | -3.72 | -3.29 | | | | ||
Growth | % | | | | | -21 | -25.1 | 11.5 | | | | ||
PE | X | | | | | N/A | N/A | N/A | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | N/A | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
